{
    "organizations": [],
    "uuid": "ebb18ce6595f8deb778b444ae59601af15655ecf",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-neurocrine-will-file-nda-for-opica/brief-neurocrine-will-file-nda-for-opicapone-for-parkinsons-disease-based-on-existing-pivotal-clinical-trial-data-idUSASB0C5R6",
    "ord_in_thread": 0,
    "title": "BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "February 14, 2018 / 9:12 PM / Updated 7 minutes ago BRIEF-Neurocrine Will File NDA For Opicapone For Parkinson's Disease Based On Existing Pivotal Clinical Trial Data Reuters Staff 1 Min Read Feb 14 (Reuters) - Neurocrine Biosciences Inc: * NEUROCRINE BIOSCIENCES WILL FILE NEW DRUG APPLICATION FOR OPICAPONE FOR PARKINSONâ€˜S DISEASE BASED ON EXISTING PIVOTAL CLINICAL TRIAL DATA * NEUROCRINE BIOSCIENCES INC - NEUROCRINE WILL PROCEED WITH PLANS TO FILE NDA FOR OPICAPONE DURING FIRST HALF OF 2019 * NEUROCRINE BIOSCIENCES INC - U.S. FDA HAS PROVIDED GUIDANCE ON REGULATORY PATH FORWARD TO SUPPORT NDA FOR OPICAPONE * NEUROCRINE BIOSCIENCES INC - NEUROLOGY DIVISION OF FDA HAS NOT REQUESTED CO TO CONDUCT AN ADDITIONAL PHASE III STUDY FOR OPICAPONE PRIOR TO NDA FILING Source text for Eikon: Further company coverage:",
    "published": "2018-02-15T05:12:00.000+02:00",
    "crawled": "2018-02-14T23:26:11.068+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "february",
        "pm",
        "updated",
        "minute",
        "ago",
        "file",
        "nda",
        "opicapone",
        "parkinson",
        "disease",
        "based",
        "existing",
        "pivotal",
        "clinical",
        "trial",
        "data",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "neurocrine",
        "bioscience",
        "inc",
        "neurocrine",
        "bioscience",
        "file",
        "new",
        "drug",
        "application",
        "opicapone",
        "parkinson",
        "disease",
        "based",
        "existing",
        "pivotal",
        "clinical",
        "trial",
        "data",
        "neurocrine",
        "bioscience",
        "inc",
        "neurocrine",
        "proceed",
        "plan",
        "file",
        "nda",
        "opicapone",
        "first",
        "half",
        "neurocrine",
        "bioscience",
        "inc",
        "fda",
        "provided",
        "guidance",
        "regulatory",
        "path",
        "forward",
        "support",
        "nda",
        "opicapone",
        "neurocrine",
        "bioscience",
        "inc",
        "neurology",
        "division",
        "fda",
        "requested",
        "co",
        "conduct",
        "additional",
        "phase",
        "iii",
        "study",
        "opicapone",
        "prior",
        "nda",
        "filing",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}